PTAFR and cancer: Given that malignant cells develop resistance to currently used EGFR-TKIs, and PAFR can mediate inactivated PTEN-induced EGFR overactivation, targeting PAFR could be exploited as a potential strategy to overcome EGFR-TKIs resistance in cancer patients having altered/mutated EGFR.